Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Veronika U%C4%8Dakar) .

1 - 10 / 89
Na začetekNa prejšnjo stran123456789Na naslednjo stranNa konec
1.
2.
The prognostic and predictive value of human gastrointestinal microbiome and exosomal mRNA expression of PD-L1 and IFNγ for immune checkpoint inhibitors response in metastatic melanoma patients : protocol trial
Ana Erman, Marija Ignjatović, Katja Leskovšek, Simona Miceska, Urša Lampreht Tratar, Maša Omerzel, Veronika Kloboves-Prevodnik, Maja Čemažar, Lidija Kandolf Sekulović, Gorazd Avguštin, Janja Ocvirk, Tanja Mesti, 2023, izvirni znanstveni članek

Povzetek: Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs). Preclinical and small cohort studies suggest gastrointestinal microbiome composition and exosomal mRNA expression of PD-L1 and IFNγ from the primary tumor, stool and body fluids as potential biomarkers for response. Methods: Patients treated with immune checkpoint inhibitors as a first line treatment for metastatic melanoma are recruted to this prospective study. Stool samples are submitted before the start of treatment, at the 12th (+/−2) week and 28th (+/−2) week, and at the occurrence of event (suspected disease progression/hyperprogression, immune-related adverse event (irAE), deterioration). Peripheral venous blood samples are taken additionally at the same time points for cytologic and molecular tests. Histological material from the tumor tissue is obtained before the start of immunotherapy treatment. Primary objectives are to determine whether the human gastrointestinal microbiome (bacterial and viral) and the exosomal mRNA expression of PD-L1 and IFNγ and its dynamics predicts the response to treatment with PD-1 and CTLA-4 inhibitors and its association with the occurrence of irAE. The response is evaluated radiologically with imaging methods in accordance with the irRECIST criteria. Conclusions: This is the first study to combine and investigate multiple potential predictive and prognostic biomarkers and their dynamics in first line ICI in metastatic melanoma patients.
Ključne besede: gastrointestinal microbiome, mRNA expression of PD-L1 and IFNγ, immune checkpoint inhibitors, metastatic melanoma
Objavljeno v DiRROS: 21.03.2024; Ogledov: 56; Prenosov: 26
.pdf Celotno besedilo (642,09 KB)
Gradivo ima več datotek! Več...

3.
Cryogenic transmission electron images of Phaeodactylum tricornutum isolates of small cellular particles
Apolonija Bedina Zavec, Darja Božič, Matej Hočevar, Aleš Iglič, Marko Jeran, Veronika Kralj-Iglič, Anna Romolo, 2024, objavljeni znanstveni prispevek na konferenci

Objavljeno v DiRROS: 08.03.2024; Ogledov: 57; Prenosov: 41
.pdf Celotno besedilo (24,27 MB)
Gradivo ima več datotek! Več...

4.
5.
Scanning electron microscope images of Phaeodactylum tricornutum culture
Apolonija Bedina Zavec, Darja Božič, Matej Hočevar, Aleš Iglič, Marko Jeran, Veronika Kralj-Iglič, Anna Romolo, 2024, objavljeni znanstveni prispevek na konferenci

Objavljeno v DiRROS: 08.03.2024; Ogledov: 61; Prenosov: 45
.pdf Celotno besedilo (56,37 MB)
Gradivo ima več datotek! Več...

6.
7.
Scanning electron microscope images of Dunaliella tertiolecta isolates of small cellular particles
Apolonija Bedina Zavec, Darja Božič, Matej Hočevar, Aleš Iglič, Marko Jeran, Anna Romolo, Veronika Kralj-Iglič, 2024, objavljeni znanstveni prispevek na konferenci

Objavljeno v DiRROS: 08.03.2024; Ogledov: 53; Prenosov: 25
.pdf Celotno besedilo (16,55 MB)
Gradivo ima več datotek! Več...

8.
Scanning electron microscope images of Dunaliella tertiolecta culture
Apolonija Bedina Zavec, Darja Božič, Matej Hočevar, Aleš Iglič, Marko Jeran, Veronika Kralj-Iglič, Anna Romolo, 2024, objavljeni znanstveni prispevek na konferenci

Objavljeno v DiRROS: 08.03.2024; Ogledov: 59; Prenosov: 33
.pdf Celotno besedilo (14,34 MB)
Gradivo ima več datotek! Več...

9.
Schedule-dependency of doxorubicin and vinblastine in EAT tumours in mice
Marija Auersperg, Ana Pogačnik, Veronika Kloboves-Prevodnik, Gregor Serša, Maja Čemažar, 2006, izvirni znanstveni članek

Povzetek: Background. Antitumour schedule-dependency of the doxorubicin and vinblastine combination was explored. Materials and methods. Intraperitoneal Ehrlich ascites tumours (EAT) syngeneic to CBA mice were treated with vinblastine ar doxorubicin alone, or in combined treatment schedules. Results. Combinations of doxorubicin and vinblasfine administered at 48-h, but not at 24-h interval,regardless of the sequence of drugs, significantly reduced the numberof tumour cells in the ascites in corrtparison with all other treatments. In the combined treatment schedules, the predominant morphologicalchanges as well as DNA distribution pattern were dependent on thefirst drug applied. Regardless of the sequence of the drugs, median survival times of animals did not significantly differ between the treatment groups. Conclusions. The effect of combination of vinblastine and doxorubicin is schedule-dependent. The time interval, but not the sequence of drugs seems to be crucial for the observed effect. The data from preclinical studies are important for planning combined treatment schedules in clinical setting.
Objavljeno v DiRROS: 15.02.2024; Ogledov: 78; Prenosov: 15
.pdf Celotno besedilo (250,21 KB)

10.
Managing anemia with epoetin alfa in patients with rectal cancer
Vaneja Velenik, Irena Oblak, Veronika Kodre, 2005, izvirni znanstveni članek

Povzetek: Background. Anemia is one of the most challenging problems in clinical oncology due to its high prevalence among the patients with malignant diseases. The purposes of our study were: (1) to assess the potential of epoetin alfa therapy to prevent the decline in Hb concentrations that typically accompanies chemotherapy/radiotherapy (ChT/RT) of the patients with rectal cancer; (2) to test the hypothesis that the use of epoetin alfa significantly reduces the transfusion requirements in the patients with rectalcancer treated with ChT/RTafter surgery, and (3) to evaluate the safety profile of the administration of epoetin alfa in the clinical setting. Methods. Sixty patients who underwent surgery for rectal cancer were prospectively enrolled. Group A consisted of 39 patients with Hb concentrations <13 g/dl at the start of ChT/RT following surgery, and group B of 17 patients with Hb concentrations >13 g/dl at the start of ChT/RT following surgery, but whose Hb concentrations fell below 13 g/dl during the ChT/RT protocol. The starting dose of epoetin alfa in both proups was 10,000 IU subcutaneously (se) three times a week (tiw). The following major parameters were evaluated: (1) change in Hb concentrations relative to the baseline as measured at 4-week intervals, (2) allogenic blood transfusion requirements in relation to Hb concentrations, and (3) incidence and severity of adverse events and their potential relationship to epoetin alfa administration. (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 14.02.2024; Ogledov: 103; Prenosov: 32
.pdf Celotno besedilo (135,72 KB)

Iskanje izvedeno v 0.34 sek.
Na vrh